| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3896 |
| Trial ID | NCT06446128 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | BCMA|CD19|D20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19/CD20 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) |
| Year | 2024 |
| Country | China |
| Company sponsor | Shanghai Cell Therapy Group Co.,Ltd |
| Other ID(s) | BZE2204-A-01 |
| Cohort 1 | |||||||||||
|
|||||||||||